XERS (Xeris Biopharma Holdings, Inc.) Stock Financials & Earnings | Market Cap Arena

XERS (Xeris Biopharma Holdings, Inc.) Stock Financials & Earnings | Market Cap Arena

XERSXeris Biopharma Holdings, Inc.

Mkt Cap$960M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$292M

Net Income (TTM)$554,000

EPS (TTM)-$0.01

Free Cash Flow (TTM)$38M

Gross Margin81.7%

Op. Margin8.5%

Net Margin0.2%

FCF Margin12.9%

P/S Ratio (TTM)3.3x

P/E Ratio (TTM)1732.6x

YoY Rev Growth+43.7%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$33M	$28M	-$13M
Q2 23	$38M	$30M	-$16M
Q3 23	$48M	$40M	-$5M
Q4 23	$44M	$34M	-$10M
Q1 24	$41M	$35M	-$14M
Q2 24	$48M	$38M	-$8M
Q3 24	$54M	$41M	-$13M
Q4 24	$60M	$51M	$2M
Q1 25	$60M	$51M	-$3M
Q2 25	$72M	$57M	$4M
Q3 25	$74M	$63M	$7M
Q4 25	$86M	$67M	$17M

Revenue Breakdown

Valuation

Quarter	P/S	P/E
Q1 23	7.9x	—
Q2 23	7.2x	—
Q3 23	6.3x	—
Q4 23	5.9x	—
Q1 24	5.6x	—
Q2 24	5.3x	—
Q3 24	5.1x	—
Q4 24	4.7x	—
Q1 25	4.3x	—
Q2 25	3.9x	—
Q3 25	3.6x	—
Q4 25	3.3x	1732.6x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$26M	-$26M
Q2 23	-$14M	-$15M
Q3 23	-$15M	-$15M
Q4 23	$6M	$6M
Q1 24	-$20M	-$20M
Q2 24	-$10M	-$11M
Q3 24	-$8M	-$8M
Q4 24	$2M	$2M
Q1 25	-$10M	-$10M
Q2 25	$182K	$10M
Q3 25	$18M	$18M
Q4 25	$20M	$20M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$238K
Q2 23	$2M
Q3 23	$345K
Q4 23	$132K
Q1 24	$164K
Q2 24	$397K
Q3 24	$87K
Q4 24	$220K
Q1 25	$13K
Q2 25	$13K
Q3 25	$363K
Q4 25	$333K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+50.4%	-9.1%
Q2 23	+50.2%	+22.1%
Q3 23	+62.6%	+9.7%
Q4 23	+33.9%	+12.2%
Q1 24	+22.4%	+18.1%
Q2 24	+26.5%	+4.2%
Q3 24	+12.3%	+26.2%
Q4 24	+35.4%	+7.7%
Q1 25	+47.9%	+15.2%
Q2 25	+48.8%	+19.2%
Q3 25	+37.1%	+0.7%
Q4 25	+42.8%	+18.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$3M	7.7%
Q2 23	$3M	7.7%
Q3 23	$2M	5.1%
Q4 23	$3M	6.2%
Q1 24	$4M	9.3%
Q2 24	$4M	8.8%
Q3 24	$7M	12.5%
Q4 24	$4M	6.0%
Q1 25	$4M	7.4%
Q2 25	$5M	7.0%
Q3 25	$8M	10.3%
Q4 25	$5M	6.1%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 23	$5M	$34M
Q2 23	$6M	$38M
Q3 23	$5M	$37M
Q4 23	$6M	$38M
Q1 24	$8M	$38M
Q2 24	$6M	$40M
Q3 24	$6M	$45M
Q4 24	$6M	$40M
Q1 25	$8M	$44M
Q2 25	$8M	$44M
Q3 25	$7M	$46M
Q4 25	$8M	$48M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$51M	$44M	$95M
Q2 23	$46M	$34M	$81M
Q3 23	$46M	$20M	$66M
Q4 23	$67M	$5M	$72M
Q1 24	$63M	$25M	$87M
Q2 24	$58M	$20M	$78M
Q3 24	$59M	$10M	$69M
Q4 24	$72M	$0	$72M
Q1 25	$58M	$0	$58M
Q2 25	$59M	$0	$59M
Q3 25	$92M	$0	$92M
Q4 25	$111M	$0	$111M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	137M	+0.9%
Q2 23	137M	+0.1%
Q3 23	138M	+0.5%
Q4 23	138M	+0.0%
Q1 24	141M	+1.7%
Q2 24	148M	+5.6%
Q3 24	149M	+0.4%
Q4 24	149M	+0.1%
Q1 25	152M	+2.2%
Q2 25	156M	+2.3%
Q3 25	178M	+13.9%
Q4 25	180M	+1.4%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 16	—	—
FY 17	—	—
FY 18	—	—
FY 19	—	—
FY 20	—	—
FY 21	$169K	294
FY 22	$311K	355
FY 23	$435K	377
FY 24	$515K	394
FY 25	$671K	435